Krish is a Partner at AIX Ventures, a top-performing AI-native investment firm, where he leads technical diligence, deal sourcing, and portfolio operations across AI, healthcare, and life sciences. He has led 45+ early- and growth-stage investments representing over $20B in cumulative enterprise value, including multiple successful exits and unicorns.

As a biomolecular engineer and AI research scientist, he has supported pioneering breakthroughs such as the world’s first AI-designed drug to reach human clinical trials and the first therapy discovered using a 3D-bioprinted tissue disease model. He has authored four internationally distributed books, serves as an Honorary Commander with the U.S. Air Force, advises leading defense and innovation initiatives, and has been featured in major global publications.

Krish holds degrees from Harvard University and the University of Oxford in Biology, Nanomedicine and Engineering.